MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from january
2024 financing, net...
$60,661K
Proceeds from january
2024 financing, net...
$4,734K
Proceeds from shares
issued in connection...
$182K
Net cash provided by
financing activities
$65,577K
Effect of exchange rate
changes on cash and cash...
$205K
Net change in cash
and cash...
-$20,185K
Canceled cashflow
$65,782K
Stock-based compensation
$8,863K
Accrued expenses
$4,477K
Accounts payable
$1,237K
Non-cash lease expense
$497K
Depreciation and
amortization
$168K
Net cash used in
operating activities
-$85,806K
Canceled cashflow
$15,242K
Net cash used in
investing activities
-$161K
Net loss
-$97,172K
Other current assets
and prepaid...
$3,161K
Operating lease
liabilities
-$506K
Other liabilities
-$209K
Purchases of property and
equipment
$161K
Back
Back
Cash Flow
source: myfinsight.com
IMMUNIC, INC. (IMUX)
IMMUNIC, INC. (IMUX)